Literature DB >> 12269826

Mechanism of antiandrogen action: key role of hsp90 in conformational change and transcriptional activity of the androgen receptor.

Virginie Georget1, Béatrice Térouanne, Jean-Claude Nicolas, Charles Sultan.   

Abstract

Activation of the androgen receptor (AR) is induced by ligand binding through conformational changes leading to control of gene expression. Antiandrogens compete with androgens for AR occupancy and subsequently block at least one step in AR action. Analysis of nuclear transfer kinetics using the GFP-AR fusion protein and partial proteolysis analysis provided evidence that the ligand-bound receptor was in equilibrium between at least two distinct conformations, leading to the production of 35 and 29 kDa trypsin-resistant fragments. It also indicated that this equilibrium may regulate the rate of nuclear transfer. The slowing of nuclear transfer by antiandrogens was correlated with the amount of receptor in conformation leading to the 35 kDa trypsin-resistant fragment. To establish the role of heat shock protein (hsp) 90 activity in antiandrogenic action, the effect of geldanamycin (GA) was evaluated in both in vitro assays and live cells. We demonstrated that in vitro hsp90s are required to stabilize the receptor in the inactive conformation and that hsp90 activity is involved in the integrity and nuclear transfer of agonist- and antagonist-bound AR. Furthermore, nuclear transfer is not the only step affected by GA since this compound was also active on a constitutively nuclear AR (GFP-NLS-AR). Hsp90 inactivation impedes interaction of androgen-bound GFP-NLS-AR with nuclear components and inhibits transcriptional activity. We conclude that hsp90s are required for the acquisition of active conformation in agonist-bound AR to regulate nuclear transfer, nuclear matrix binding, and transcriptional activity. Pure antiandrogens block the transconformational change of AR in an intermediary complex unable to acquire the active conformation and to dissociate the hsp90.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12269826     DOI: 10.1021/bi0259150

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  57 in total

1.  Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance.

Authors:  Katherine J O'Malley; Gabrielle Langmann; Junkui Ai; Raquel Ramos-Garcia; Robert L Vessella; Zhou Wang
Journal:  Prostate       Date:  2011-12-07       Impact factor: 4.104

2.  Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment.

Authors:  Hardik J Patel; Shanu Modi; Gabriela Chiosis; Tony Taldone
Journal:  Expert Opin Drug Discov       Date:  2011-05       Impact factor: 6.098

3.  The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells.

Authors:  Anthony J Saporita; Junkui Ai; Zhou Wang
Journal:  Prostate       Date:  2007-04-01       Impact factor: 4.104

Review 4.  Gene targeting to the stroma of the prostate and bone.

Authors:  Roger S Jackson; Omar E Franco; Neil A Bhowmick
Journal:  Differentiation       Date:  2008-05-20       Impact factor: 3.880

5.  Filamin-A fragment localizes to the nucleus to regulate androgen receptor and coactivator functions.

Authors:  C J Loy; K S Sim; E L Yong
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-07       Impact factor: 11.205

6.  Antischistosomal versus antiandrogenic properties of aryl hydantoin Ro 13-3978.

Authors:  Chunkai Wang; Qingjie Zhao; Jaeki Min; Sakthivel Muniyan; Mireille Vargas; Xiaofang Wang; Yuxiang Dong; R Kiplin Guy; Ming-Fong Lin; Jennifer Keiser; Jonathan L Vennerstrom
Journal:  Am J Trop Med Hyg       Date:  2014-03-31       Impact factor: 2.345

Review 7.  Sex differences in vascular physiology and pathophysiology: estrogen and androgen signaling in health and disease.

Authors:  Austin C Boese; Seong C Kim; Ke-Jie Yin; Jean-Pyo Lee; Milton H Hamblin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-06-16       Impact factor: 4.733

8.  AR inhibitors identified by high-throughput microscopy detection of conformational change and subcellular localization.

Authors:  Jeremy O Jones; W Frank An; Marc I Diamond
Journal:  ACS Chem Biol       Date:  2009-03-20       Impact factor: 5.100

Review 9.  Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy.

Authors:  Jason P Chua; Andrew P Lieberman
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-12       Impact factor: 4.388

10.  Repositioning Dopamine D2 Receptor Agonist Bromocriptine to Enhance Docetaxel Chemotherapy and Treat Bone Metastatic Prostate Cancer.

Authors:  Yang Yang; Kenza Mamouni; Xin Li; Yanhua Chen; Sravan Kavuri; Yuhong Du; Haian Fu; Omer Kucuk; Daqing Wu
Journal:  Mol Cancer Ther       Date:  2018-06-15       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.